Mitchell J. Bartlett - Publications

2016-2019 Pharmacology University of Arizona, Tucson, AZ 

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Ye T, Bartlett MJ, Sherman SJ, Falk T, Cowen SL. Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine. Experimental Neurology. 113670. PMID 33662379 DOI: 10.1016/j.expneurol.2021.113670  0.6
2021 Young KF, Gardner R, Sariana V, Whitman SA, Bartlett MJ, Falk T, Morrison HW. Can quantifying morphology and TMEM119 expression distinguish between microglia and infiltrating macrophages after ischemic stroke and reperfusion in male and female mice? Journal of Neuroinflammation. 18: 58. PMID 33618737 DOI: 10.1186/s12974-021-02105-2  0.6
2020 Bartlett MJ, Mabrouk OS, Szabò L, Flores AJ, Parent KL, Bidlack JM, Heien ML, Kennedy RT, Polt R, Sherman SJ, Falk T. The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia. International Journal of Molecular Sciences. 22. PMID 33374986 DOI: 10.3390/ijms22010020  0.6
2020 Bartlett MJ, Flores AJ, Ye T, Smidt SI, Dollish HK, Stancati JA, Farrell DC, Parent KL, Doyle KP, Besselsen DG, Heien ML, Cowen SL, Steece-Collier K, Sherman SJ, Falk T. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental Neurology. 113413. PMID 32717354 DOI: 10.1016/J.Expneurol.2020.113413  0.6
2020 Crown LM, Bartlett MJ, Wiegand JL, Eby AJ, Monroe EJ, Gies K, Wohlford L, Fell MJ, Falk T, Cowen SL. Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease. Frontiers in Neurology. 11: 324. PMID 32477237 DOI: 10.3389/Fneur.2020.00324  0.6
2020 Bartlett MJ, So LY, Szabò L, Skinner DP, Parent KL, Heien ML, Vanderah TW, Polt R, Sherman SJ, Falk T. Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. Bmc Research Notes. 13: 149. PMID 32164786 DOI: 10.1186/S13104-020-04994-7  0.6
2019 Hay M, Polt R, Heien ML, Vanderah TW, Largen-Milnes TM, Rodgers KE, Falk T, Bartlett MJ, Doyle K, Konhilas J. A Novel Angiotensin-(1-7)-glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation Related Memory Dysfunction. The Journal of Pharmacology and Experimental Therapeutics. PMID 30709867 DOI: 10.1124/Jpet.118.254854  0.6
2018 Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. Neuropharmacology. 141: 260-271. PMID 30201210 DOI: 10.1016/J.Neuropharm.2018.09.005  0.6
2018 Ye T, Bartlett MJ, Schmit MB, Sherman SJ, Falk T, Cowen SL. Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations. Frontiers in Neural Circuits. 12: 61. PMID 30150926 DOI: 10.3389/Fncir.2018.00061  0.6
2015 Bartlett MJ, Joseph RM, LePoidevin LM, Parent KL, Laude ND, Lazarus LB, Heien ML, Estevez M, Sherman SJ, Falk T. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model. Neuroscience Letters. PMID 26644333 DOI: 10.1016/J.Neulet.2015.11.047  0.44
2014 Flores AJ, Bartlett MJ, So LY, Laude ND, Parent KL, Heien ML, Sherman SJ, Falk T. Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model. Neuroscience Letters. 564: 48-52. PMID 24525249 DOI: 10.1016/J.Neulet.2014.02.004  0.44
Show low-probability matches.